Evotec Initiates Phase I Clinical Studies of Anti-Inflammatory Drug
Posted on: Friday, 10 October 2008, 09:00 CDT
Evotec a developer of small molecule drugs, has initiated Phase I clinical studies for its proprietary, small molecule P2X7 receptor antagonist.
The first Phase I study is a double-blind and placebo-controlled single ascending dose study in healthy male volunteers to evaluate the compound's safety, tolerability, pharmacokinetic profile and pharmacodynamic effects after oral administration.
The P2X7 receptor is an ATP-gated ion channel primarily expressed on cells of the immune system and is thought to play an important role in inflammatory processes through the regulation of a number of proinflammatory cytokines.
P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions, which affect millions of individuals, the company said.
Michael Kelly, president of Renovis, Evotec's US subsidiary, said: "We are extremely pleased to announce the achievement of this second important clinical milestone at our US site following its integration into Evotec earlier in 2008. The initiation of Phase I studies with our P2X7 receptor antagonist is the culmination of the efforts of many of our dedicated R&D staff over the past few years and we have high expectations as we progress further into development."
Source: Datamonitor
Related Articles
- One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials
- Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
- CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
- Axelar Initiates Phase I/II Cancer Trial
- Merck's Investigational Lipid-Modifier, CORDAPTIVE(TM) (ER Niacin/Laropiprant), Positively Affected Key Lipid Parameters With Less Flushing, In Data From Phase III Study
- Athersys Begins Phase I Trial for ATHX-105 for Treatment of Obesity Milestone for Company's Lead Program in Emerging Clinical Pipeline
- Adolor Corporation Initiates Phase 1 Multi-Dose Study of Novel Delta Opioid Agonist for the Management of Pain
- Actelion-1 -- First Tissue-Targeting Endothelin Receptor Antagonist -- in Phase III for Pulmonary Hypertension
- ArQule Initiates Phase 1 Trial With ARQ 171, Provides Enrollment Update on ARQ 501 and ARQ 197
- Adolor Corporation Initiates Phase 1 Study of Novel Delta Opioid Agonist for the Management of Pain
 |
 |
User Comments (0)
RSS Feeds